Lung cancer management in 2010

Apar Kishor P Ganti, Chao H. Huang, Mark A. Klein, Sean Keefe, Michael J. Kelley

Research output: Contribution to journalReview article

14 Scopus citations


The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.

Original languageEnglish (US)
Issue number1
StatePublished - Jan 2011


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ganti, A. K. P., Huang, C. H., Klein, M. A., Keefe, S., & Kelley, M. J. (2011). Lung cancer management in 2010. ONCOLOGY, 25(1).